title: Sentinel lymph node biopsy in male breast cancer patients.
abstract: The concept of sentinel node biopsy has been validated for female breast cancer patients whereas, ALND remains the standard of care for male breast cancer patients with similar tumours. We evaluated the results of SLN biopsy in male breast cancer patients with clinically negative axillae. This study included all male breast cancer patients who underwent SLN biopsy between February 1998 and October 2003. All patients had negative axillae on clinical examination. All patients underwent pre-operative lymphoscintigraphy. SLN biopsy was performed using a combination of Patent blue V and 99mTc-radiolabelled colloidal albumin injected peritumourally. Nine patients, 26-79 years of age, were included in the study. Pre-operative lymphoscinitgraphy identified SLNs in all patients. Intraoperatively, SLNs were successfully localised in all patients. The mean number of SLNs encountered was 2.4. Five patients had a positive SLN, four a negative SLN. Five patients (one with a negative SLN, four with a positive SLN) had been elected pre-operatively to undergo ALND regardless of findings on SLN biopsy. ALND confirmed the SLN to be negative in one patient (false-negative rate: 0%) and three of the four patients with positive SLN(s) had additional positive nodes in the axilla. SLN biopsy accurately predicted axillary lymph node status in these five patients. These findings compare favourably with findings reported in the literature regarding SLN biopsy in female breast cancer patients. SLN biopsy accurately staged the axilla in male breast cancer patients and should be considered for axillary staging in male breast cancer patients with clinically negative axillae.
authors.affiliation: Department of Surgery, University of Wales College of Medicine, Cardiff, UK.
authors.forename: A
authors.initials: A
authors.lastname: Goyal
authors.forename: K
authors.initials: K
authors.lastname: Horgan
authors.forename: M
authors.initials: M
authors.lastname: Kissin
authors.forename: C
authors.initials: C
authors.lastname: Yiangou
authors.forename: M
authors.initials: M
authors.lastname: Sibbering
authors.forename: M
authors.initials: M
authors.lastname: Lansdown
authors.forename: R G
authors.initials: RG
authors.lastname: Newcombe
authors.forename: R E
authors.initials: RE
authors.lastname: Mansel
authors.forename: U
authors.initials: U
authors.lastname: Chetty
authors.forename: P
authors.initials: P
authors.lastname: Ell
authors.forename: L
authors.initials: L
authors.lastname: Fallowfield
authors.forename: M
authors.initials: M
authors.lastname: Kissin
mesh_terms: D000328:Adult; D000368:Aged; D001365:Axilla; D018567:Breast Neoplasms, Male / Q000175:diagnosis* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000473:pathology; D018275:Carcinoma, Lobular / Q000175:diagnosis* / Q000473:pathology; D005188:False Negative Reactions; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D021701:Sentinel Lymph Node Biopsy; D013671:Technetium Tc 99m Sulfur Colloid; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D019275:Radiopharmaceuticals; D013671:Technetium Tc 99m Sulfur Colloid